All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

In a Surprise Finding, Gene Mutation Found Linked to Low-Risk Bladder Cancer

October 16th 2013

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

High Bile VEGF Levels Suggest Pancreatic Cancer

October 16th 2013

A VEGF level greater than 0.5 ng/mL in bile aspirated from the pancreas was 93% effective at identifying pancreatic cancer in patients with biliary stricture

AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability

October 15th 2013

Additional investment in and collaboration with ADC Therapeutics

Researchers identify four genetic variants that are linked to esophageal cancer and its precursor, Barrett's esophagus

October 14th 2013

Findings from the first large-scale, genome-wide association study of esophageal adenocarcinoma may lead to new screening tools for those at high risk.

Abiraterone Stalls Pain, Quality of Life Decline in mCRPC

October 11th 2013

Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.

Positive Idelalisib Data Ends Late-Stage CLL Trial

October 10th 2013

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

Does Good Cholesterol Increase Breast Cancer Risk?

October 10th 2013

A protein receptor for the "good cholesterol," HDL, may help make breast cancer more aggressive and offer a new target for treating the disease.

Safety Concerns Halt Ponatinib Development

October 9th 2013

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib, following the high occurrence of arterial thrombosis in patients treated with the drug.

When More Medicine Isn't Always Better: Penn Study Reveals High Costs of Unnecessary Radiation Treatments for Terminal Cancer Patients

October 9th 2013

More than 95 Percent of Advanced Prostate Cancer Patients Receive Multiple Radiation Treatments for Pain Control, Despite Evidence Pointing to Equal Benefit from Single Treatments

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Association of Community Cancer Centers' 2013 Innovator Award Recipients Take Spotlight at National Oncology Conference

October 8th 2013

Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers' 2013 Innovator Awards.

National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million

October 7th 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

New ASCO/CAP Guideline Enhances HER2 Testing in Breast Cancer

October 7th 2013

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

Redheads and Melanoma

October 7th 2013

Underlying mechanism for increased risk now defined.

Free Head, Neck Cancer Screenings Have Positive Impact in Urban Areas

October 4th 2013

Offering free head and neck cancer screenings annually to the community not only has the possibility of early detection, but also the opportunity â€“ particularly in an urban city â€“ to increase a person's understanding of risk factors that cause cancer, according to a new study from Henry Ford Hospital in Detroit.

ACCC Institute Calls for Collaboration, Adaptation to Maximize Patient Care Delivery amid Consolidation

October 4th 2013

In response to the growing trend of hospital consolidation, including questions about cancer care decision-making, cost impacts, and delivery of care, the ACCC Institute for the Future of Oncology has released a new white paper that provides perspectives on how these alignments are affecting cancer care providers, cancer programs, and the patients they serve.

Merrimack Pharmaceuticals Completes Enrollment of Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

October 3rd 2013

Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.

Early Results Show Promise for Anti-PD-1 Antibody MK-3475 in NSCLC

October 2nd 2013

The investigational immunotherapy MK-3475 has demonstrated an objective response rate of up to 24% in patients with previously treated non-small cell lung cancer

AJMC Study: If the Doctor Recommends it, Telephone Counseling May Increase Colorectal Screening

October 1st 2013

A study of three diverse primary care practices tests the effectiveness of having doctors recommend counseling for colorectal cancer screening. Results found many patients do not follow through with the referral, but for those that do, some change their mind and have a test they might have avoided.

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus

October 1st 2013

Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.